卵巢上皮性癌组织中激肽释放酶7及14的表达及临床意义

山东大学学报(医学版)

卵巢上皮性癌组织中激肽释放酶7及14的表达及临床意义

顾双¹，王青²，张意茗³，袁彩霞¹，张向宁¹

1. 山东大学齐鲁医院妇产科，济南 250012； 2. 枣庄市山亭区人民医院妇产科，山东枣庄 277145；3. 济南市中心医院生殖医学科，济南 250013

收稿日期:2007-12-02 修回日期:1900-01-01 出版日期:2008-02-16 发布日期:2008-02-16
通讯作者: 张向宁

Expressions of kallikrein 7 and 14 in human epithelial ovarian cancer and its clinical significance

GU Shuang¹，WANG Qing²，ZHANG Yi-ming³，YUAN Cai-xia¹，ZHANG Xiang-ning¹

1. Department of Gynecology and Obstetrics, Qilu Hospital of Shandong University, Jinan 250012, China; 2. Department of Obstetrics and Gynecology, People′s Hospital of Shanting District, Zaozhuang 277145

Received:2007-12-02 Revised:1900-01-01 Online:2008-02-16 Published:2008-02-16
Contact: ZHANG Xiang-ning

摘要/Abstract

摘要： 目的研究激肽释放酶（kallikrein, KLK）7及KLK14在卵巢上皮性癌组织中的表达,并探讨其临床意义。方法采用RT-PCR及Westernblot技术测定KLK7及KLK14 在50例不同临床分期、不同组织分级的卵巢上皮性癌中mRNA及蛋白表达。结果KLK7在卵巢癌中表达明显增高，且低分化组织较高分化组织表达高（P＜0.01）；KLK14在卵巢癌中表达亦增高（P＜0.05），且晚期卵巢癌(Ⅲ、Ⅳ期)明显高于早期卵巢癌(Ⅰ、Ⅱ期，P＜0.01)；G3级卵巢癌高于G1、G2级卵巢癌（P＜0.05）。结论KLK7、KLK14在卵巢癌的发生及转移中有潜在促进作用。

Abstract: To evaluate the expressions of kallikrein 7(KLK7) and 14(KLK14) in human epithelial ovarian cancers and to discuss its clinical significance in malignant tumors. Methods RT-PCR and Westernblot were used to determine the expressions of KLK7 and KLK14 mRNA and proteins in 50 epithelial ovarian cancers with different clinical stages and different histological grades. ResultsThe expressions of KLK7 mRNA and protein in ovarian cancers were significantly higher than those in benign tumors（P＜0.01）and were markedly associated with the histological differentiation （P＜0.01）, also the expressions of KLK14 mRNA and protein in ovarian cancers were higher than those in benign tumors（P＜0.05）and were associated with the histological differentiation(P＜0.05), and the expression of KLK14 in advanced stages (Ⅲ and Ⅳ stage) was higher than that in early stages (Ⅰ　and Ⅱ　stage, P＜ 0.01). ConclusionKLK7 and KLK14 play potential roles in the pathogenesis and metastasis of ovarian cancer.

Key words: Kallikrein 7, Kallikrein 14, Ovarian neoplasms

中图分类号:

R737.31

顾双,王青,张意茗,袁彩霞,张向宁 . 卵巢上皮性癌组织中激肽释放酶7及14的表达及临床意义[J]. 山东大学学报(医学版), 2008, 46(2): 200-203.

GU Shuang,WANG Qing,ZHANG Yi-ming,YUAN Cai-xia,ZHANG Xiang-ning. Expressions of kallikrein 7 and 14 in human epithelial ovarian cancer and its clinical significance[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2008, 46(2): 200-203.

参考文献

相关文章 15

[1]	王谋龙,陈永坤,邢德广,曲良锁,王成伟. 经颅多普勒超声早期预测动脉瘤夹闭术后迟发性脑缺血的临床分析[J]. 山东大学学报（医学版）, 2017, 55(11): 38-41.
[2]	陆衡,刘延国,李曙光,陈晓康,田琦,衣翠华,王秀问. YKL-40对卵巢癌SKOV-3细胞迁移能力的影响[J]. 山东大学学报（医学版）, 2017, 55(1): 33-38.
[3]	赵路,矫俊,张腾,焦薪霖,崔保霞. 肝X受体在卵巢癌组织中的表达及T0901317在卵巢癌细胞系SKOV3中的作用[J]. 山东大学学报（医学版）, 2017, 55(1): 49-53.
[4]	赵云霞,宋静,张灿灿,林雪艳,尉蔚,田永杰. CXXC4增强上皮性卵巢癌细胞对化疗药物的敏感性[J]. 山东大学学报（医学版）, 2016, 54(3): 24-29.
[5]	徐志宏,吴小华,姚铁柱,王晓翔,段晓阳,史健. mir-99a的表达与上皮性卵巢癌患者预后的关系[J]. 山东大学学报（医学版）, 2016, 54(3): 77-80.
[6]	张春霞,邹存华,宋冬冬,余江. P38MAPK信号通路对卵巢癌中尿激酶型纤维蛋白酶原激活剂的影响[J]. 山东大学学报（医学版）, 2016, 54(2): 68-74.
[7]	吕树卿, 尉蔚, 张灿灿, 田永杰. HGF/PARP-1信号通路调控卵巢癌细胞侵袭转移的作用[J]. 山东大学学报（医学版）, 2015, 53(7): 1-7.
[8]	付伟1，高文娟2，张志勉1，曲迅2，赵玉霞3. 罗勒多糖对卵巢癌SKOV3细胞VEGF受体表达的调控作用及对其侵袭能力的影响[J]. 山东大学学报（医学版）, 2014, 52(5): 39-43.
[9]	李燕，尉蔚，吕树卿，田永杰. PARP-1对卵巢癌血管生成的影响[J]. 山东大学学报（医学版）, 2014, 52(4): 97-101.
[10]	贾宗洋,张向宁,靳艳慧,魏美玲. PD98059联合顺铂对卵巢癌细胞增殖的影响[J]. 山东大学学报(医学版), 2013, 51(2): 27-32.
[11]	丁佰娟，张友忠，吕昌帅，姜侃，刘洪丽. TMPyP4-PDT对人宫颈癌细胞的杀伤效应[J]. 山东大学学报(医学版), 2012, 50(11): 53-57.
[12]	张敬敬1，王哲1，田永杰1，张捷2. PJ34对卵巢癌C13*细胞生长活性及耐药性的影响[J]. 山东大学学报(医学版), 2012, 50(1): 46-50.
[13]	刘敏1,2，王莉2，周婷2，荣风年2. PR/AR基因多态性与上皮性卵巢癌易感性的研究[J]. 山东大学学报(医学版), 2011, 49(9): 144-148.
[14]	康马飞，卜庆，刘瑛，骆梅青，廖漓漓，涂江江. 培美曲塞单药或联合奈达铂治疗对卡铂及紫杉醇耐药的复发晚期上皮性卵巢癌[J]. 山东大学学报(医学版), 2011, 49(5): 122-124.
[15]	阚艳艳1，张敬敬1，王哲1，田永杰1，戚晓霞2，张捷3. RNA干扰抑制PARP-1基因表达对卵巢癌细胞增殖及耐药性的影响[J]. 山东大学学报(医学版), 2011, 49(4): 52-56.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed